Generation Bio (NASDAQ:GBIO) Receives “Buy” Rating from Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of Generation Bio (NASDAQ:GBIO) in a report released on Friday,Benzinga reports. They currently have a $15.00 price objective on the stock.

Several other equities research analysts have also weighed in on GBIO. Canaccord Genuity Group upped their price objective on Generation Bio from $9.00 to $10.00 and gave the company a “buy” rating in a research note on Monday, August 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Generation Bio in a research report on Wednesday, October 8th. Wedbush lowered Generation Bio from an “outperform” rating to a “neutral” rating and set a $7.00 price target on the stock. in a research report on Wednesday, August 13th. Finally, Wall Street Zen cut Generation Bio from a “hold” rating to a “sell” rating in a research note on Saturday, July 26th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $10.67.

Generation Bio Trading Up 7.0%

GBIO traded up $0.36 during midday trading on Friday, reaching $5.47. The company’s stock had a trading volume of 100,490 shares, compared to its average volume of 144,516. Generation Bio has a twelve month low of $3.00 and a twelve month high of $23.80. The stock has a market cap of $36.87 million, a P/E ratio of -0.59 and a beta of 2.51. The company has a fifty day simple moving average of $5.95 and a 200 day simple moving average of $4.89.

Generation Bio (NASDAQ:GBIO) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.82) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.18) by $2.36. The business had revenue of $1.59 million for the quarter, compared to the consensus estimate of $0.66 million. Generation Bio had a negative net margin of 410.13% and a negative return on equity of 94.82%. Sell-side analysts expect that Generation Bio will post -1.75 earnings per share for the current year.

Institutional Trading of Generation Bio

A number of large investors have recently added to or reduced their stakes in GBIO. Y Intercept Hong Kong Ltd acquired a new stake in Generation Bio in the 2nd quarter valued at about $47,000. Nuveen LLC acquired a new position in shares of Generation Bio during the 1st quarter worth approximately $69,000. Militia Capital Partners LP acquired a new stake in Generation Bio during the 2nd quarter valued at $174,000. Marshall Wace LLP acquired a new position in shares of Generation Bio in the second quarter valued at $37,000. Finally, Acadian Asset Management LLC raised its position in shares of Generation Bio by 54.3% in the first quarter. Acadian Asset Management LLC now owns 1,159,135 shares of the company’s stock valued at $468,000 after purchasing an additional 407,843 shares during the period. Institutional investors and hedge funds own 95.22% of the company’s stock.

Generation Bio Company Profile

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.